HER dimerization inhibitors: Developing pertuzumab as an anticancer agent in women's oncology

Don S. Dizon, Sharmila K. Makhija

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Pertuzumab is a novel monoclonal antibody that blocks the dimerization domain of the human epidermal growth factor receptor (HER)-2/neu receptor, disabling its ability to form heterodimers with the other members of its family. Objective: We review the background and scientific rationale, but more specifically cover current clinical trial outcomes of pertuzumab in solid tumors, with an emphasis on the work completed in women's cancers. Methods: Clinical trial results published or presented at national meetings are included in this review. Results: Pertuzumab shows promising activity with trastuzumab in the treatment of metastatic breast cancer. The results in ovarian cancer have been limited thus far but a post hoc analysis of the results of a completed randomized Phase II trial of gemcitabine with or without pertuzumab suggests that low HER3 levels may mark a group of women who may benefit from the addition of pertuzumab to chemotherapy. Conclusions: The efficacy of pertuzumab independent of HER-2/neu overexpression remains under investigation. Still, the benefits seen in HER-2/neu positive breast cancer is encouraging. Work in ovarian cancer remains preliminary but the possibility of using pertuzumab in a targeted population with low HER3 levels warrants further evaluation.

Original languageEnglish (US)
Pages (from-to)1363-1369
Number of pages7
JournalExpert Opinion on Drug Discovery
Volume3
Issue number11
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Dimerization
Antineoplastic Agents
gemcitabine
Ovarian Neoplasms
Clinical Trials
ErbB-2 Receptor
Breast Neoplasms
Aptitude
pertuzumab
Neoplasms
Monoclonal Antibodies
Drug Therapy
Population

Keywords

  • Breast cancer
  • EGFR pathway
  • HER dimerization inhibitors
  • HER-2/neu
  • Ovarian cancer

ASJC Scopus subject areas

  • Drug Discovery

Cite this

HER dimerization inhibitors : Developing pertuzumab as an anticancer agent in women's oncology. / Dizon, Don S.; Makhija, Sharmila K.

In: Expert Opinion on Drug Discovery, Vol. 3, No. 11, 11.2008, p. 1363-1369.

Research output: Contribution to journalArticle

@article{66a57a8abbf6442e9ddefde1f151da93,
title = "HER dimerization inhibitors: Developing pertuzumab as an anticancer agent in women's oncology",
abstract = "Background: Pertuzumab is a novel monoclonal antibody that blocks the dimerization domain of the human epidermal growth factor receptor (HER)-2/neu receptor, disabling its ability to form heterodimers with the other members of its family. Objective: We review the background and scientific rationale, but more specifically cover current clinical trial outcomes of pertuzumab in solid tumors, with an emphasis on the work completed in women's cancers. Methods: Clinical trial results published or presented at national meetings are included in this review. Results: Pertuzumab shows promising activity with trastuzumab in the treatment of metastatic breast cancer. The results in ovarian cancer have been limited thus far but a post hoc analysis of the results of a completed randomized Phase II trial of gemcitabine with or without pertuzumab suggests that low HER3 levels may mark a group of women who may benefit from the addition of pertuzumab to chemotherapy. Conclusions: The efficacy of pertuzumab independent of HER-2/neu overexpression remains under investigation. Still, the benefits seen in HER-2/neu positive breast cancer is encouraging. Work in ovarian cancer remains preliminary but the possibility of using pertuzumab in a targeted population with low HER3 levels warrants further evaluation.",
keywords = "Breast cancer, EGFR pathway, HER dimerization inhibitors, HER-2/neu, Ovarian cancer",
author = "Dizon, {Don S.} and Makhija, {Sharmila K.}",
year = "2008",
month = "11",
doi = "10.1517/17460441.3.11.1363",
language = "English (US)",
volume = "3",
pages = "1363--1369",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - HER dimerization inhibitors

T2 - Developing pertuzumab as an anticancer agent in women's oncology

AU - Dizon, Don S.

AU - Makhija, Sharmila K.

PY - 2008/11

Y1 - 2008/11

N2 - Background: Pertuzumab is a novel monoclonal antibody that blocks the dimerization domain of the human epidermal growth factor receptor (HER)-2/neu receptor, disabling its ability to form heterodimers with the other members of its family. Objective: We review the background and scientific rationale, but more specifically cover current clinical trial outcomes of pertuzumab in solid tumors, with an emphasis on the work completed in women's cancers. Methods: Clinical trial results published or presented at national meetings are included in this review. Results: Pertuzumab shows promising activity with trastuzumab in the treatment of metastatic breast cancer. The results in ovarian cancer have been limited thus far but a post hoc analysis of the results of a completed randomized Phase II trial of gemcitabine with or without pertuzumab suggests that low HER3 levels may mark a group of women who may benefit from the addition of pertuzumab to chemotherapy. Conclusions: The efficacy of pertuzumab independent of HER-2/neu overexpression remains under investigation. Still, the benefits seen in HER-2/neu positive breast cancer is encouraging. Work in ovarian cancer remains preliminary but the possibility of using pertuzumab in a targeted population with low HER3 levels warrants further evaluation.

AB - Background: Pertuzumab is a novel monoclonal antibody that blocks the dimerization domain of the human epidermal growth factor receptor (HER)-2/neu receptor, disabling its ability to form heterodimers with the other members of its family. Objective: We review the background and scientific rationale, but more specifically cover current clinical trial outcomes of pertuzumab in solid tumors, with an emphasis on the work completed in women's cancers. Methods: Clinical trial results published or presented at national meetings are included in this review. Results: Pertuzumab shows promising activity with trastuzumab in the treatment of metastatic breast cancer. The results in ovarian cancer have been limited thus far but a post hoc analysis of the results of a completed randomized Phase II trial of gemcitabine with or without pertuzumab suggests that low HER3 levels may mark a group of women who may benefit from the addition of pertuzumab to chemotherapy. Conclusions: The efficacy of pertuzumab independent of HER-2/neu overexpression remains under investigation. Still, the benefits seen in HER-2/neu positive breast cancer is encouraging. Work in ovarian cancer remains preliminary but the possibility of using pertuzumab in a targeted population with low HER3 levels warrants further evaluation.

KW - Breast cancer

KW - EGFR pathway

KW - HER dimerization inhibitors

KW - HER-2/neu

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=56749185664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749185664&partnerID=8YFLogxK

U2 - 10.1517/17460441.3.11.1363

DO - 10.1517/17460441.3.11.1363

M3 - Article

C2 - 23496170

AN - SCOPUS:56749185664

VL - 3

SP - 1363

EP - 1369

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 11

ER -